Unlocking ocular biomarkers for early detection of Alzheimer's disease

IF 11.1 1区医学 Q1 CLINICAL NEUROLOGY Alzheimer's & Dementia Pub Date : 2025-02-19 DOI:10.1002/alz.14567

Nikhil Dave, Melissa Lee, Hania Pavlou, Owen Im, Kim Goh, Sam Ulin, Kristina Malzbender, Eli Shobin, Aishwarya Sukumar

{"title":"Unlocking ocular biomarkers for early detection of Alzheimer's disease","authors":"Nikhil Dave, Melissa Lee, Hania Pavlou, Owen Im, Kim Goh, Sam Ulin, Kristina Malzbender, Eli Shobin, Aishwarya Sukumar","doi":"10.1002/alz.14567","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD). After interviews with neurologists, optometrists, primary care physicians, and ophthalmologists, the potential for ocular biomarker testing to become a standard clinical practice in the future was assessed. Ocular tests offer a non-invasive alternative to blood-based testing, capturing a substantial niche of ≈ 4 to 8 million individuals in the United States during routine eye exams. Technical requirements for broad adoption include high accuracy comparable to blood-based tests and 510(k) clearance. Ocular biomarker technology must meet the practical requirements of optometrists and ophthalmologists, including ease of implementation, automation, and a clear path to profitability. A sufficient body of evidence to support guideline inclusion, reimbursement, and clinical actionability will facilitate the adoption. As the field evolves, advances such as earlier detection of preclinical AD may further expand the role of ocular testing.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Ocular biomarkers offer another non-invasive alternative to blood-based Alzheimer's disease testing.</li>\n \n <li>Wide adoption will require accuracy akin to blood-based tests and 510(k) clearance.</li>\n \n <li>Ocular screening could benefit ≈ 4 to 8 million US individuals conducting routine eye exams.</li>\n \n <li>Current ocular offerings remain nascent, and advances could expand this reach.</li>\n \n <li>New technology must show ease of implementation, automation, and a path to profit.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14567","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14567","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer's disease (AD). After interviews with neurologists, optometrists, primary care physicians, and ophthalmologists, the potential for ocular biomarker testing to become a standard clinical practice in the future was assessed. Ocular tests offer a non-invasive alternative to blood-based testing, capturing a substantial niche of ≈ 4 to 8 million individuals in the United States during routine eye exams. Technical requirements for broad adoption include high accuracy comparable to blood-based tests and 510(k) clearance. Ocular biomarker technology must meet the practical requirements of optometrists and ophthalmologists, including ease of implementation, automation, and a clear path to profitability. A sufficient body of evidence to support guideline inclusion, reimbursement, and clinical actionability will facilitate the adoption. As the field evolves, advances such as earlier detection of preclinical AD may further expand the role of ocular testing.

Highlights

Ocular biomarkers offer another non-invasive alternative to blood-based Alzheimer's disease testing.
Wide adoption will require accuracy akin to blood-based tests and 510(k) clearance.
Ocular screening could benefit ≈ 4 to 8 million US individuals conducting routine eye exams.
Current ocular offerings remain nascent, and advances could expand this reach.
New technology must show ease of implementation, automation, and a path to profit.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

解锁眼部生物标志物用于阿尔茨海默病的早期检测。

最近的证据表明，眼部检查有望成为一种非侵入性的、具有成本效益的老年痴呆症（AD）早期检测方法。在采访了神经科医生、验光师、初级保健医生和眼科医生后，评估了眼科生物标志物检测在未来成为标准临床实践的潜力。眼科检查为血液检查提供了一种非侵入性替代方法，在美国常规眼科检查中占有约400万至800万人的可观份额。广泛采用的技术要求包括与血液检测相当的高精度和510(k)清除率。眼部生物标志物技术必须满足验光师和眼科医生的实际要求，包括易于实施、自动化和明确的盈利途径。有足够的证据来支持指南的纳入、报销和临床可操作性，将有助于指南的采用。随着该领域的发展，临床前AD的早期检测等进步可能会进一步扩大眼科检查的作用。眼部生物标志物为血液检测阿尔茨海默病提供了另一种非侵入性替代方法。广泛采用将需要类似于血液检测和510(k)许可的准确性。眼部筛查可使约400万至800万进行常规眼科检查的美国人受益。目前的视觉产品仍处于初级阶段，技术进步可能会扩大这一范围。新技术必须表现出易于实施、自动化和盈利途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.